Fig. 7

The in vivo therapeutic efficacy of RBC-NPs and metabolism of RBC-NPs and GST-ETX in lung. A Schematic illustration of the experiment. Four groups of mice were administered 50 ng GST-ETX via trachea; 10 min later, two treatment groups of mice were administered 2 mg RBC-NPs via trachea or intravenous, and a positive control group of mice was administered PBS via trachea. A negative control group of mice were administered PBS via trachea twice. B Schematic illustration of the experiment. Three groups of mice were administered 50 ng GST-ETX via trachea, 10 min later, treatment groups of mice were administered 2 mg RBC-NPs via trachea, and a positive control group of mice were administered PBS from tracheas. At the same time, a negative control group of mice were administered PBS via trachea twice. C Schematic illustration of metabolism experiment. Two groups of mice were administered 12.5 ng Cy5.5-ETX via trachea; 10 min later, the treatment group of mice were administered 2 mg DiR-RNPs via trachea, and the positive control group of mice were administered PBS from trachea. D Survival curves of mice over 14 days post-infection (n = 6). E, F Blood cell counts in mice (n = 3). G The chemical composition analysis of serum (n = 3). H Representative sections made from various organs of experimental mice, stained with H&E (scale bar: 200 μm). I In vitro fluorescence images of DiR in liver and spleen. J In vitro fluorescence images of Cy5.5 in liver and spleen. Data are presented as mean ± SD. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p ≥ 0.05 (ns)